Treatment of Neuromyelitis Optica: Review and Recommendations.

Treatment of Neuromyelitis Optica: Review and Recommendations.

Pokaż inne wersje (1)

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to tr...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Kimbrough, D, Fujihara, K, Jacob, A, Lana-Peixoto, M, Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, de Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG, Wingerchuk, D
Format:	Journal article
Język:	English
Wydane:	2012

Podobne zapisy

Treatment of neuromyelitis optica: Review and recommendations
od: Kimbrough, D, i wsp.
Wydane: (2012)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Pittock, S, i wsp.
Wydane: (2019)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
od: Jyh Yung Hor, i wsp.
Wydane: (2020-06-01)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
od: Mealy, M, i wsp.
Wydane: (2014)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
od: Fujihara, K, i wsp.
Wydane: (2014)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
od: Collongues, N, i wsp.
Wydane: (2013)

Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
od: Douglas Kazutoshi Sato, i wsp.
Wydane: (2014-06-01)

Treatment of neuromyelitis optica: an evidence based review
od: Douglas Sato, i wsp.
Wydane: (2012-01-01)

The borderland of neuromyelitis optica.
od: Matthews, L, i wsp.
Wydane: (2009)

Neuromyelitis optica associated with systemic autoimmune diseases in children
od: Russo RA, i wsp.
Wydane: (2008-09-01)

Atypical presentations of neuromyelitis optica
od: Douglas Sato, i wsp.
Wydane: (2011-10-01)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
od: Kim, W, i wsp.
Wydane: (2012)

Use of mitoxantrone in neuromyelitis optica.
od: Kitley, J, i wsp.
Wydane: (2011)

Current and future treatment approaches for neuromyelitis optica
od: Nicolas Collongues, i wsp.
Wydane: (2011-03-01)

Differential diagnosis of neuromyelitis optica spectrum disorders
od: Sung-Min Kim, i wsp.
Wydane: (2017-07-01)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
od: Nour, M, i wsp.
Wydane: (2014)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
od: Elsone, L, i wsp.
Wydane: (2012)

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
od: Cree, BAC, i wsp.
Wydane: (2019)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, i wsp.
Wydane: (2015)

Magnetic resonance imaging in neuromyelitis optica.
od: Tackley, G, i wsp.
Wydane: (2014)

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica
od: Nicolas Collongues, i wsp.
Wydane: (2016-05-01)

A practical guide to the treatment of neuromyelitis optica.
od: Palace, J, i wsp.
Wydane: (2012)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
od: Sato, D, i wsp.
Wydane: (2014)

Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes
od: Marco A. Lana-Peixoto, i wsp.
Wydane: (2019-06-01)

The evolving clinical spectrum of neuromyelitis optica
od: Viegas, S, i wsp.
Wydane: (2008)

Devic’s neuromyelitis optica: a critical review Neuromielite óptica de Devic: revisão crítica
od: Marco Aurélio Lana-Peixoto
Wydane: (2008-03-01)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
od: Achim Berthele, i wsp.
Wydane: (2023-04-01)

Prevalence and clinical characteristics of neuromyelitis optica spectrum disorders patients with myelin oligodendrocyte glycoprotein antibodies
od: Sato, D, i wsp.
Wydane: (2013)

A mathematical model of cellular swelling in Neuromyelitis optica
od: Laranjeira, S, i wsp.
Wydane: (2017)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i wsp.
Wydane: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i wsp.
Wydane: (2013)

Racial differences in neuromyelitis optica spectrum disorder
od: Kim, S, i wsp.
Wydane: (2018)

NMO-IgG in the diagnosis of neuromyelitis optica.
od: Jarius, S, i wsp.
Wydane: (2007)

Neuromyelitis Optica
od: Goyal V, i wsp.
Wydane: (2009-10-01)

Neuromyelitis optica
od: Jacob Anu, i wsp.
Wydane: (2007-01-01)

Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews
od: Ju-Hong Min, i wsp.
Wydane: (2023-02-01)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Nour, M, i wsp.
Wydane: (2015)

Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.
od: Lucy Matthews, i wsp.
Wydane: (2015-01-01)

Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: therapeutic implications
od: Romain Marignier, i wsp.
Wydane: (2010-09-01)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
od: Viegas, S, i wsp.
Wydane: (2009)